Skip to content
← Lobby register
GT
Public Authority

Gavi, the Vaccine Alliance

🇪🇺 SWITZERLANDRegistered 27/02 staff
Disclosed budget
€100,000 — €199,999
Meetings 12mo
5
Policy files
0
Accredited passes
0

Recent meetings

DateCommissioner / CabinetTopicFile
21 Jan 2026
Jasna Pajnkihar
Cabinet member
Exchange of views on emergency health preparednessSRC
21 Jan 2026
Hadja Lahbib
Commissioner
Exchange of views on emergency health preparedness
21 Jan 2026
Jasna Pajnkihar
Cabinet member
Exchange of views on emergency health preparedness
12 Jun 2025
Patricia Reilly
Cabinet member
planning for the Gavi Global Summit – 25 June 2025SRC
12 Jun 2025
Patricia Reilly
Cabinet member
planning for the Gavi Global Summit – 25 June 2025
20 May 2025
Florika Fink-Hooijer
Director-General
Introductory meeting with GAVISRC
20 May 2025
Florika Fink-Hooijer
Director-General
Introductory meeting with GAVI
18 Mar 2025
Hana Genorio
Cabinet member
Global Summit: Health & Prosperity through Immunisation
18 Mar 2025
Hana Genorio
Cabinet member
Global Summit: Health & Prosperity through ImmunisationSRC
31 Jan 2025
Martin Seychell
Deputy Director-General
Update on the developments - Gavi 6.0 High-Level Pledging Summit state of play and next steps
31 Jan 2025
Martin Seychell
Deputy Director-General
Update on the developments - Gavi 6.0 High-Level Pledging Summit state of play and next stepsSRC
31 Jan 2025
Cecile Billaux
Head of Unit
Update on the developments - Gavi 6.0 High-Level Pledging Summit state of play and next stepsSRC
31 Jan 2025
Cecile Billaux
Head of Unit
Update on the developments - Gavi 6.0 High-Level Pledging Summit state of play and next steps
24 Jan 2025
Martin Seychell
Deputy Director-General
Exchange of views on the GAVI 6.0 High-Level Pledging Summit state of play and next steps
24 Jan 2025
Martin Seychell
Deputy Director-General
Exchange of views on the GAVI 6.0 High-Level Pledging Summit state of play and next stepsSRC
11 Dec 2024
Koen Doens
Director-General
Introductory meeting
11 Dec 2024
Koen Doens
Director-General
Introductory meetingSRC
16 Sept 2024
Koen Doens
Director-General
Follow up callSRC
16 Sept 2024
Koen Doens
Director-General
Follow up call
11 Sept 2024
Koen Doens
Director-General
VaccineSRC
11 Sept 2024
Koen Doens
Director-General
Vaccine
18 Jan 2024
Wopke Hoekstra
Commissioner
Global vaccination trends; climate change and health
18 Jan 2024
Wopke Hoekstra
Commissioner
Global vaccination trends; climate change and healthSRC
16 May 2023
Renaud Savignat
Cabinet member
Exchange of views on the partnership between EU and GAVI
16 May 2023
Renaud Savignat
Cabinet member
Exchange of views on the partnership between EU and GAVISRC

Mission & Goals

Gavi’s mission is: “Saving children’s lives and protecting people’s health by increasing equitable use of vaccines in lower-income countries." The Gavi Alliance promotes health by: (i) providing vaccines and the means to deliver such vaccines to people in the poorest countries; (ii) facilitating the research and development of vaccines of primary interest to the developing world; and (iii) providing support in connection with achieving the foregoing purposes by helping to strengthen health care systems and civil societies supporting such purposes in the developing world. Gavi co-led COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator.

EU Legislative Interests

European Consensus on Development EU Strategy on Africa EU Global Health Strategy Global Gateway MAV+ Initiative Global COVID-19 vaccine response EU Global Health Resilience Initiative The EU Medical Countermeasures Strategy

Communication Activities

Global Gateway Summit Global Health Policy Forum Regular calls with DG INTPA (donor calls)

Interests Represented

Promotes their own interests or the collective interests of their members

Member Of

The Board is comprised of 18 “representative” seats, 9 seats for independent or “unaffiliated” individuals and one seat for Gavi's CEO. The Board’s representative seats ensure that institutions and constituencies can provide formal input into the development of all Gavi’s policies and the management of its operations. UNICEF, WHO, the World Bank and the Bill & Melinda Gates Foundation hold permanent seats on the Board. Constituency representatives serve on a time-limited basis. Board members include representation from donor governments, implementing country governments, civil society organisations and the vaccine industry. Independent Board members are private individuals with no professional connection to Gavi’s work. They bring independent and balanced scrutiny to all of the Board’s deliberations. These individuals also provide expertise in a number of critical areas such as investment, auditing and fundraising.

Organisation Members

The Gavi Board is responsible for strategic direction and policy-making, oversees the operations of the Vaccine Alliance and monitors programme implementation. With membership drawn from a range of partner organisations, as well as experts from the private sector, the Gavi Board provides a forum for balanced strategic decision making, innovation and partner collaboration. Gavi partners are represented through 18 seats on the Board with nine seats reserved for independent or unaffiliated individuals. Committees support the development of key policies, oversee specific activities and are comprised of Board members, alternates, and in some instances delegates with expertise in critical areas. The Board is the supreme governing body of Gavi, the Vaccine Alliance. Certain functions are reserved to the Board, including the setting of policies and strategies for Gavi, and amending its by-laws and other internal guidelines and procedures necessary for the administration and management of the Vaccine Alliance. The Board delegates certain activities and areas of work to five standing Board committees and one Advisory committee, staffed by Board members, alternates, and in certain instances independent experts or partner representatives. The committees include: • Programme and Policy Committee; • Governance Committee; • Investment Committee; • Audit & Finance Committee; and • Evaluation Advisory Committee.

Additional Information

EU 13 2nd Instalment Nov-24 EUR 135,000,000.00 EC AVMA 2025 Instalment Dec-25 EUR 185,400,000.00 EC HSS 6.0 2025 Instalment Dec-25 EUR 4,500,000.00 EC HSS 6.0 2025 Instalment Dec-25 EUR 10,500,000.00